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Purpose: IgPro20, Hizentra® an L-prolinestabi-
lized 20% human subcutaneous immunoglobulin
(SCIG), has been shown in a Phase III pivotal study
to be well tolerated and efﬁcacious in adult and
pediatric Japanese patients with primary immunodeﬁ-
ciency. Economic aspects of SCIG treatment in compar-
ison with previous intravenous immunoglobulin (IVIG)
therapy were analyzed in this Phase III study in Japan.
Methods: Twenty-four Japanese patients with pri-
mary immunodeﬁciency on IVIG treatment were
switched to IgPro20 at an equivalent dose (full
analysis set). The study consisted of a screening
period, an IVIG treatment period with 3 planned
infusions every 3 or 4 weeks, a 12-week SCIG wash-
in and wash-out period, and a 12-week SCIG efﬁcacy
period. The difference in medical cost and productiv-
ity loss resulting from changes in hospital frequency
between the SCIG and IVIG treatment was evaluated.
Information about treatment cost was collected as
part of the Life Quality Index questionnaire. In
addition, productivity loss and hospital-related absen-
teeism were evaluated.
Findings: Life Quality Index scores for all domains
were higher with SCIG than with IVIG in this patient
population. In the full analysis set, the mean (SD) Life
Quality Index score of the Costs domain increased
from 45.1 (26.34) at Week 1 (IVIG period) to 71.9
(18.52) at Week 24 (end of the SCIG efﬁcacy period),
representing a mean change of 26.74 and a large score
improvement effect size (1.01). Median productivity
loss was reduced by 60% from baseline to Weeks 12
and 24. This resulted in a reduction in costs of JPY
10,875 per patient per month at Weeks 12 and 24.
Subcutaneous treatment with IgPro20 also reduced1616hospital-related absenteeism. The number of patients,
parents, or guardians who were not absent from work
or housework duties and had no reduction in working
time increased from 4 (17.4%) at Week 1 to 9
(39.1%) at Week 24. Similar results were obtained
in the per-protocol set (n ¼ 21).
Implications: Switching from IVIG to SCIG reduced
markedly productivity loss and hospital-related ab-
senteeism. The reduction in hospital visit frequency
due to the use of home-based IgG therapy enabled by
the change in administration route is expected to
produce an important pharmacoeconomic beneﬁt in
Japan. Study Code: ZLB06_002CR, ClinicalTrials.
gov identiﬁer: NCT01199705. (Clin Ther.
2014;36:1616–1624) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: cost minimization, home-based ther-
apy, immunoglobulin replacement therapy, pharma-
coeconomics, productivity loss, subcutaneous IgG.INTRODUCTION
Primary immunodeﬁciency diseases (PID) include a
range of disorders that are characterized by an
intrinsic defect in the immune system, predisposing
the patient to recurrent infections.1–3 Patients with
PID require regular administration of immunoglobulin
G (IgG) to prevent infection and maintain quality of
life. Prevalence of PID in Japan was determined in aVolume 36 Number 11
A. Igarashi et al.recent nationwide survey (n = 1240) to be 2.3 patients
with PID per 100,000 inhabitants, with minimal
variations across the country regions.4
The current standard practice for PID treatment in
Japan is intravenous IgG (IVIG) treatment every 3 or
4 weeks. Subcutaneous IgG (SCIG) administration has
been used in Scandinavian countries for many decades
and is now becoming more popular in the rest of the
world due to the availability of 16% and 20% SCIG
products.5–7 SCIG treatment is rarely associated with
systemic adverse events and infusion-related reactions
are usually mild.7–10 There are no venous access issues
with SCIG, which is a particular advantage in in-
fants.7,9 In addition, SCIG administration results in
stable serum IgG levels compared with the peak and
trough concentrations characteristic of IVIG.7,10,11
Last but not least, although IVIG requires a hospital
visit for its administration, SCIG can be administered
at home by self-infusion or by caregivers (parents or
guardians).
IgPro20* (L-proline–stabilized 20% human SCIG)
is a concentrated SCIG with established efﬁcacy and
tolerability in patients with PID. A Phase III pivotal
study of IgPro20 in Japanese patients with PID
showed that weekly SCIG treatment with IgPro20
was effective in pediatric and adult patients and was
tolerated well.12 The results obtained concur with
those seen in previous European13 and North
American10 trials of IgPro20, suggesting that SCIG
could be an alternative treatment opportunity in
Japan. IgPro20 has recently been approved in Japan
for the treatment of PID and secondary immuno-
deﬁciency.
Several studies have shown or suggested a reduc-
tion in costs with SCIG treatment compared with
IVIG treatment.14–17 In Germany, SCIG was found to
be 50% less expensive than IVIG due to the reduced
costs for treatment procedures and the avoided ab-
sence from work.15 SCIG was predicted to be more
cost-effective than hospital-based IVIG in Canada.17
Additional studies are needed to evaluate the costs of
SCIG versus IVIG, mainly focusing on the difference
in medical cost as well as productivity loss, resulting
from the difference in hospital-visit frequency. Eco-
nomic aspects of SCIG treatment in comparison with
previous IVIG therapy analyzed in the Phase III
pivotal study in Japan are reported here.*Trademark: Hizentras (CSL Behring, Berne, Switzerland).
November 2014METHODS
Study Design
This study aimed to evaluate the economic value, in
terms of cost of health care, of SCIG with IgPro20
versus IVIG in patients with PID by performing a cost-
minimization analysis focused on changes in produc-
tivity loss due to the difference in administration
route. The cost-minimization analysis was conducted
as part of the Japanese pivotal Phase III study for
IgPro20 (Study Code: ZLB06_002CR, ClinicalTrials.
gov identiﬁer: NCT01199705).12 This study was
designed as a prospective, multicenter, open-label,
single-arm study with comparison of clinical outcomes
before and after switch to treatment with IgPro20.
Patients with PID on IVIG treatment (ambulatory
care) were switched to self-infusion of subcutaneous
IgPro20 at an equivalent dose. The study consisted of
a screening period, an IVIG treatment period with
3 planned infusions every 3 or 4 weeks, a 12-week
SCIG wash-in and wash-out period, and a 12-week
SCIG efﬁcacy period followed by a completion or
discontinuation visit. The study was approved by
Independent Ethics Committee and Institutional Re-
view Board at each site.
Patients
Patients with PID requiring immunoglobulin-
replacement therapy who completed the study were
included in the pharmacoeconomic analysis.
Pharmacoeconomic Assessments
SCIG self-infusion of IgPro20 at Week 24 was
compared with ambulatory care with IVIG at Week 1
(baseline data). The inﬂuence of SCIG treatment on
pharmacoeconomics and health-related quality of life
in patients with PID was evaluated by several patient-
reported outcomes. Information about treatment cost
was collected as part of the Life Quality Index (LQI)
questionnaire, domain Costs.18 The LQI included 15
questions addressing the following domains: Treat-
ment Interference (interference of IgG therapy with
work, school, family, and social life), Therapy-Related
Problems (convenience of infusions, their painfulness,
their impact on health improvement), Therapy Setting
(how pleasant and convenient the environment was in
which treatment was conducted), and Costs (cost of
therapy and transportation to and from the location
of therapy), as well as Total Score describing health-
related quality of life overall.1617
Clinical TherapeuticsPharmacoeconomic assessment of IVIG and SCIG
treatments nonmedical costs, such as travel expenses
associated with hospital visit, was performed based on
a questionnaire of medical expenditures of IVIG and
SCIG treatments (referred to as “medical expenditure
questionnaire”). Medical cost, such as cost of exper-
imental drugs, was not evaluated, as this analysis
focused on changes in cost derived from the difference
in administration route rather than evaluating a
potential difference between IVIG and SCIG medica-
tion costs. In Japan, the cost of IVIG and SCIG
therapies is generally similar.
In addition, productivity loss was calculated by
multiplying the hospital-related absenteeism, or work-
day loss, by the mean gross wage in Japan. Hospital-
related absenteeism was collected via a patient, parent,
or guardian medical expenditure questionnaire (Table I).
Productivity loss among patients and their caregivers
(parents or guardians) was calculated using this
questionnaire. Productivity loss was analyzed with the
number of patients, parents, or guardians who were
absent from work or from housework duties because of
hospital visit. The patient, parent, or guardian medical
expenditure questionnaire included questions relating to
hospital-related absenteeism from work or housework
duties, as well as instructions on how to complete the
questionnaire and background information. The ques-
tionnaire was completed by the patient (for patients
older than 14 years at study start) or the parent orTable I. Questions asked to the patients or guardian du
Question No.
24 How many days were you off for that
25 How many days did you reduce work f
26 How much time did you reduce work,
(1/4, half, or 3/4 of the day)?
27 How many days was your guardian off
28 How many days did your guardian redu
29 How much time did your guardian red
(1/4, half, or 3/4 of the day)?
*Questions 24 to 26 were answered by adults (18 years of age or
of age (at the start of the study). Questions 27 to 29 were answ
same individuals completed the questionnaire throughout the st
the questions (patient 603, at Week 1 for questions 27 and 28
1618legally acceptable representative (for children younger
than 14 years at study start).
The mean productivity loss was calculated by
multiplying the total number of working hours lost
(TWHL) by the mean wage per hour. The mean daily
working time published by the Japanese Government
was 8.06 hours in 2010.19 TWHL was calculated for
each patient by the following formula: TWHL ¼ 8.06
hours  (reported number of days off [question {Q}
24 or Q26, Table I] þ reported number of days with
reduced work [Q25 or Q27]  work reduction factor
[Q26 or Q29]). Mean gross wage per hour was JPY
1799 in 2010, quoted from the Ofﬁcial Statistics
published by the Japanese Ministry of Health, Labor
and Welfare.20 The mean gross wage included basic
wages, assignment allowance, regular attendance
allowance, commuter allowance, and family allowance,
as well as overtime work allowance. Therefore, the
mean productivity loss ¼ 1799  TWHL.
The medical expenditure questionnaire and the 4
domains of the LQI Questionnaire (Treatment Inter-
ference, Therapy-Related Problems, Therapy Setting,
and Costs) were completed at the same time at Week 1
(before the ﬁrst SCIG treatment), at Week 12 (at
completion of the wash-in and wash-out period), and
at Week 24 (at completion of the evaluation period).
The cost-minimization analysis of IVIG and SCIG
treatment was based on the fact that the efﬁcacy of
these 2 treatments was comparable, as reportedring the visits.
Question*
month because of your hospital visit?
or that month because of your hospital visit?
on average, compared with the usual time
for that month because of your hospital visit?
ce work for that month because of your hospital visit?
uce work, on average, compared with the usual time
older) and the guardians of children younger than 14 years
ered by the guardians of patients aged 14 to 18 years. The
udy. Only 1 patient reported “I don’t know” to at least 1 of
and at Week 24 for question 27).
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IgPro20 treatment resulted in equivalent serum IgG
levels compared with previous IVIG treatment.12
Cost-minimization analysis is an appropriate ap-
proach when alternative therapies have identical out-
comes, but differ in costs.21,22 Cost components that
were identical between 2 arms were excluded, and we
focused on difference of costs between each arm. The
pharmacoeconomic analysis was based on societal
perspective because it is considered the broadest
perspective.21,23
Data were managed using an Oracle Clinical data-
base. Computerized and visual checks for complete-
ness and plausibility were performed. Data were
analyzed using SAS software, version 9.2 or higher
(SAS Institute, Cary, North Carolina).
Statistical Analysis
Two population subsets deﬁned in the clinical study
were used for pharmacoeconomic analysis: the full
analysis set (FAS) included all patients treated with
IgPro20 during the efﬁcacy period; the per-protocol
set (PPS) included all patients who had received at
least 6 doses of IVIG at 3- to 4-week intervals,
followed by uniform weekly SCIG infusions until at
least Week 16, with at least one documented total
serum IgG trough level in the efﬁcacy period. Data
were analyzed by descriptive statistics and summar-
ized by number of patients, mean, SD, 0% (mini-
mum), 25%, 50% (median), 75%, and 100%
(maximum) quantiles. Sensitivity analysis was not
performed due to small sample size. Changes in LQI
scores from Week 1 to Week 24 were assessed by total
score and each individual domains. LQI effect size was
calculated from the mean change from Week 1 to
Week 24 divided by the SD of Week 1. Strength of
improvement was calculated by effect size (small >0.2,
medium >0.5, and large >0.8) as described previ-
ously.24 No imputation for missing data or patients
discontinuing the study was performed.
RESULTS
This multicenter study was conducted in 9 sites in
Japan. Twenty-ﬁve patients of Asian origin were
enrolled. One patient discontinued the study during
the wash-in and wash-out period due to relocation;
24 patients (9 females and 15 males; mean [SD] age,
20.5 [13.5] years; range 358 years) completed
the study.12 IgPro20 treatment resulted in a lowNovember 2014incidence of infections (2.98 infections/patient/year,
no serious bacterial infection was reported), hospi-
talizations (0.55 days/patient/year), and days out of
work, school, kindergarten, or daycare or unable to
perform normal daily activities due to infections
(3.48 days/patient/year), and was well tolerated (the
majority of the causally related adverse events
[91.3%] were mild local reactions). Efﬁcacy and
safety proﬁle with IgPro20 were comparable with
the previous IVIG replacement therapy. A dose-
equivalent switch to SCIG treatment with IgPro20
was effective in maintaining total serum IgG trough
levels equal to or above those achieved on the
previous IVIG therapy. The geometric mean ratios of
IgG trough levels on SCIG versus IVIG were 1.11 (2-
sided 90% conﬁdence interval, 1.081.15) in the FAS
(n ¼ 24) and 1.09 (2-sided 90% conﬁdence interval,
1.061.13) in the PPS (n ¼ 21); conﬁdence intervals
were within the accepted equivalence range 0.80 to
1.25.12
LQI scores for all domains were higher with SCIG
than with IVIG in this patient population (Figure 1).
The mean (SD) LQI total score increased in the FAS
from 53.7 (19.53) at Week 1 to 71.5 (15.14) at Week
24, representing a mean change of 17.85 and a large
score improvement effect size (0.91). Similar results
were observed in the PPS; the mean change in LQI
total score was 16.21, with a corresponding score
improvement effect size of 0.85. The largest improve-
ment effect was reported in the “Costs” domain for
SCIG therapy with IgPro20 with a score improvement
of 1.01 (FAS) and 1.08 (PPS) (the mean [SD] LQI
score increased from 45.1 [26.34] at Week 1 to 71.9
[18.52] at Week 24 in the FAS and from 43.7 [25.99]
at Week 1 to 70.6 [18.37] at Week 24 in the PPS,
representing a mean change of 26.74 and 26.99,
respectively).
Median productivity loss was reduced substantially
by 60% (in the FAS and PPS) from Week 1 (IVIG
period) to Week 12 (end of the wash-in and wash-out
period; Table II and Figure 2). A similar reduction (by
60% in the FAS and 50% in the PPS) in the median
productivity loss was seen from Week 1 to Week 24
(end of the SCIG efﬁcacy period). This resulted in a
reduction by JPY 10,875 in FAS at Weeks 12 and 24
(JPY 10,875 at Week 12, and JPY 7250 at Week 24 in
the PPS) of median productivity loss per patient per
month. Mean productivity loss decreased from Week
1 to Weeks 12 and 24 by 26% to 38% in the FAS and1619
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Figure 1. Life Quality Index scores with subcutaneous immunoglobulin (SCIG) and intravenous immunoglo-
bulin (IVIG). Mean Life Quality Index scores were reported at Week 1 and Week 24 and rated for
different domains. Results were graded as a score out of 100 (maximum) for full analysis set (FAS)
(upper panel) and per-protocol set (PPS) (lower panel).
Clinical Therapeutics29% to 32% in the PPS. Individual productivity loss
results were scattered up to JPY 72,500; for one third
of the data points, no productivity loss was reported
(21 of 70 individual data points were JPY 0, Figure 2).
Hospital-related absenteeism with IgPro20 was
compared with IVIG therapy for patients and guard-
ians (Table III). The number of patients, parents, or
guardians who were not absent from work or
housework duties and had no reduction in working1620time increased from 4 (17.4%) at Week 1 (IVIG
period) to 9 patients (39.1%) at Week 24 (SCIG
period) in the FAS, and increased from 4 patients
(20.0%) at Week 1 (IVIG period) to 7 patients
(35.0%) at Week 24 (SCIG period) in the PPS. Eight
patients, parents, or guardians who were absent from
work or housework duties at Week 1 did not miss any
days at Week 24, including 5 individuals who also
had no days with reduction in working time atVolume 36 Number 11
Table II. Mean productivity* loss with IgPro20† compared with intravenous immunoglobulin therapy. Data are given in JPY.
Values
Week 1‡ IVIG Week 12§ SCIG Week 24|| SCIG
FAS PPS FAS PPS FAS PPS
n 23 20 24 21 23 20
Mean (SD) 20,962 (18,156) 21,569 (19,449) 12,990 (15,038) 14,327 (15,612) 15,446 (20,454) 14,862 (19,070)
Median 18,125 16,312 7250 7250 7250 9062
Range 072,500 072,500 058,000 058,000 072,500 072,500
FAS ¼ full analysis set; IVIG ¼ intravenous immunoglobulin; PPS ¼ per-protocol set; SCIG ¼ subcutaneous immunoglobulin.
*Productivity loss was calculated by multiplying the hospital-related absenteeism, or work-day loss, by the mean wage in Japan. One patient did not provide answers
to the corresponding questions at Week 1 and Week 24, but answered at Week 12. That patient was part of FAS and PPS. No imputation was made for missing data.
†Trademark: Hizentras (CSL Behring, Berne, Switzerland).
‡Week 1: reﬂects IVIG period.
§Week 12: reﬂects wash-in and wash-out period.
||Week 24: reﬂects efﬁcacy period.
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Table III. Decrease of hospital-related absenteeism for patients and guardians with IgPro20* compared with
intravenous immunoglobulin therapy.†
Week 1 IVIG Week 24 SCIG
Population Not Absent‡ No Reduction§
Not Absent and
no Reduction Not Absent‡ No Reduction§
Not Absent and
no Reduction
FAS
n 8 9 4 14 14 9
N 23 23 23 23 24 23
% 34.8 39.1 17.4 60.9 58.3 39.1
PPS
n 8 8 4 12 11 7
N 20 20 20 20 21 20
% 40.0 40.0 20.0 60.0 52.4 35.0
FAS ¼ full analysis set; N ¼ total number of patients; n ¼ number of patients, parents, or guardians; IVIG ¼ intravenous
immunoglobulin; PPS ¼ per-protocol set; SCIG ¼ subcutaneous immunoglobulin.
*Trademark: Hizentras (CSL Behring, Berne, Switzerland).
†Number of patients, parents, or guardians not absent from work or from housework duties because of hospital visits was
evaluated.
‡Not absent (question 24 and question 27) ¼ During the most recent 1 month, were there any days that you (or “your
guardian”) could not do your (his or her) job or your (his or her) housework for an entire day because of your hospital visit?
§No reduction (question 25 and question 28) ¼ During the most recent 1 month, were there any days that you (or “your
guardian”) reduced the time for your (his or her) job or your housework (his or her) because of your hospital visit?
Clinical TherapeuticsWeek 24 (FAS). For only 2 of 23 patients, an increase
in absenteeism was observed from not absent at
Week 1 to Z1 missed or reduced day at Week 24
(FAS). These results suggested that SCIG treatment
reduced the burden of IgG replacement therapy for
patients, parents, and guardians compared with IVIG
treatment.
DISCUSSION
Productivity loss and hospital-related absenteeism were
reduced markedly after switching from IVIG to SCIG,
and clinical outcomes were similar to previous IVIG.
These results are even more striking when considering
that, due to the switch and the study design, patients
were required to visit the hospital more often during
the beginning of SCIG infusion period than during
IVIG treatment to be trained in IgG self-administration.
The most common perspectives for pharmacoeconomic
analyses are those of providers, payers, patients, and
society. The societal perspective is broadest and is often
preferred, as it includes all different points of view.21,23
A recent Japanese guideline for health economic1622analyses allowed including societal perspective for
productivity loss analyses.25 The burden of lifelong
IgG treatment for PID requires involvement of patients
and caregivers, particularly for children, and has an
important societal impact, resulting in productivity
loss.
Nonmedical treatment costs were assessed as part
of the LQI analysis and LQI score improved with
SCIG compared with IVIG. The costs captured in this
trial include those of the initial training in IgG self-
administration. The productivity loss per patient per
month was reduced by approximately JPY 10,000
(median, FAS). It can be assumed that, in routine care,
the difference of costs between SCIG and IVIG might
increase further, as hospital visits will decrease once
the self-infusion can be accurately and routinely
performed at home. Overall, weekly SCIG treatment
with IgPro20 greatly reduced patients’, parents’, or
guardians’ productivity losses and hospital-related
absenteeism compared with IVIG therapy. As patients
with PID require life-long therapy, these savings
should occur every year.Volume 36 Number 11
A. Igarashi et al.The assessments of nonmedical treatment cost and
productivity loss showed an improvement with SCIG
home therapy compared with hospital-based IVIG in
Japan. A Swedish study estimated that the yearly cost
per patient for the health care sector should decrease
by USD 10,100 (cost estimate for 1993) with the use
of SCIG home therapy instead of IVIG infusions at the
hospital.16 In Italy, the yearly overall cost was
estimated to decrease by EUR 1361 by switching
patients with chronic inﬂammatory demyelinating
polyneuropathy from IVIG to SCIG.26 In Germany,
the yearly saving for the health care sector with
changing 60% of patients with PID from IVIG to
SCIG was estimated to be EUR 1777 million.15
CONCLUSIONS
The reduction in hospital visit frequency due to the
use of home-based therapy enabled by the change in
administration route is expected to produce an im-
portant pharmacoeconomic beneﬁt in Japan.
Limitations of our study are the nonrandomized
design and the small sample size. The latter does not
allow performing statistical hypothesis testing, nor
subgroup or sensitivity analyses.
Nevertheless, the results reported here contribute to
the growing evidence showing that SCIG therapy is
associated with cost savings or is at least cost neutral
compared with IVIG.
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